Stockscreener 앱 받기
92.95
0.77%
0.71
시간 외 거래:
92.95
전일 마감가:
$92.24
열려 있는:
$91.88
하루 거래량:
1.33M
Relative Volume:
0.70
시가총액:
$18.50B
수익:
$5.14B
순이익/손실:
$1.29B
주가수익비율:
14.52
EPS:
6.4034
순현금흐름:
$1.33B
1주 성능:
+1.00%
1개월 성능:
-8.63%
6개월 성능:
+7.42%
1년 성능:
+54.04%
1일 변동 폭
$91.72
$93.57
1주일 범위
$91.15
$94.91
52주 변동 폭
$53.56
$112.29
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
92.95 | 18.36B | 5.14B | 1.29B | 1.33B | 6.4034 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-02-05 | 개시 | H.C. Wainwright | Buy |
| 2026-01-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 개시 | Barclays | Overweight |
| 2025-06-16 | 업그레이드 | Stifel | Hold → Buy |
| 2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
Incyte (NASDAQ: INCY) R&D head exercises options, sells 18,667 shares - Stock Titan
Incyte Corp Stock (ISIN: US45337C1027) Faces Pressure Amid Oncology Pipeline Setbacks and Market Vol - AD HOC NEWS
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Incyte Corp. (INCY) reports Q4 2025 revenue growth of 28% to $1.51B driven by Jakafi and Opzelura sales - MSN
Faithward Advisors LLC Takes $4.45 Million Position in Incyte Corporation $INCY - MarketBeat
Incyte (INCY) Strengthens Partnership with Knight for MINJUVI in Latin America - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Form 144: INCY (NASDAQ: INCY) reports 18,667-share stock option sale - Stock Titan
INCY's phase III Monjuvi study meets key goals in first-line lymphoma - MSN
Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue (NASDAQ:INCY) - Seeking Alpha
INCY News | INCYTE CORP (NASDAQ:INCY) - ChartMill
INCY wins EC approval for label expansion of oncology drug Zynyz - MSN
How Diverging Zynyz Outcomes In Cancer Trials At Incyte (INCY) Have Changed Its Investment Story - simplywall.st
Incyte (INCY) Downgraded by Jefferies; Price Target Lowered | IN - GuruFocus
Jefferies downgrades Incyte stock rating on patent cliff concerns - Investing.com
Incyte Drug Zynyz Approved in Europe for Anal Canal Cancer Treatment - MyChesCo
How Investors Are Reacting To Incyte (INCY) Winning EU Approval For Zynyz In Advanced Anal Cancer - Yahoo Finance
Incyte Corporation (NASDAQ:INCY) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
INCYIncyte Corp Stock Price and Quote - Finviz
European Commission Approves J&J Prostate Drug, PLX Fabry Dosing, Incyte's Zynyz Second Indication - RTTNews
Mackenzie Financial Corp Has $38.43 Million Stock Holdings in Incyte Corporation $INCY - MarketBeat
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte (INCY) Down 4.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Incyte Sets December Investor Lineup as Pipeline Progress Draws Market Attention - MSN
Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Incyte Advances New Early Stage Drug INCA033989 Into Human Testing - TipRanks
Incyte at Barclays Conference: Navigating Post-Jakafi Future - Investing.com
Russell Investments Group Ltd. Has $68.44 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Korea Investment CORP Raises Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte at Leerink Global Healthcare Conference: Strategic Growth Focus - Investing.com
Incyte Corporation $INCY Shares Purchased by Vestcor Inc - MarketBeat
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz - Finviz
Incyte becomes third company to receive CRL over issues at Novo Indiana factory - Endpoints News
Stifel reiterates Incyte stock rating after FDA setback - Investing.com
Incyte (NASDAQ:INCY) Receives Buy Rating from HC Wainwright - MarketBeat
WINTON GROUP Ltd Acquires 213,557 Shares of Incyte Corporation $INCY - MarketBeat
A Glimpse Into The Expert Outlook On Incyte Through 13 Analysts - Benzinga
INCY: Today's Analyst Rating Update by HC Wainwright & Co. | INC - GuruFocus
Incyte wins EC approval of Zynyz for SCAC - The Pharmaletter
Meiji Yasuda Asset Management Co Ltd. Has $2.34 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) - BioSpace
Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp - MSN
Incyte Corporation $INCY Stake Reduced by Vinva Investment Management Ltd - MarketBeat
Assessing Incyte (INCY) Valuation After EC Approval Of Zynyz For Advanced Anal Cancer - simplywall.st
FDA Declines New Indication for Incyte's (INCY) Zynyz Due to Man - GuruFocus
Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant - Seeking Alpha
Incyte (INCY) Gains EC Approval for Combination Therapy with Zyn - GuruFocus
Incyte Corporation (INCY) Receives FDA Complete Response Letter for Zynyz® sBLA - GuruFocus
FDA issues complete response letter for Incyte’s Zynyz application in lung cancer - Investing.com
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):